EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Disease trajectory and competing risks of patients with cirrhosis in the US

Mohsen Mohammadi, Bima J Hasjim, Salva N Balbale, Praneet Polineni, Alexander A Huang, Mitchell Paukner, Therese Banea, Oriana Dentici, Dominic J Vitello, Joy E Obayemi, Andrés Duarte-Rojo, Satish N Nadig und 4 weitere

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0313152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Mohsen Mohammadi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Northwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center (CTC), Northwestern University, Chicago,…. Hauptthemen laut MEDLINE: Liver Cirrhosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIA NIH HHS, NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cirrhosis is a dynamic disease process leading to liver-related death, which has increased by over 65% over the last decade. Unpredictable hepatic decompensation complications are a major source of morbidity and mortality. Thus, accurately characterizing disease progression through discrete stages of cirrhosis is critical towards implementing timely intervention and liver transplant (LT) waitlisting.

Methods

A retrospective, longitudinal, population-cohort study of adult patients with cirrhosis from a US metropolitan area (2006–2012) was conducted. Clinical diagnoses were defined by ICD-9 and CPT codes. Cirrhosis stages were defined as: compensated without portal hypertension (Stage 1), compensated with portal hypertension (Stage 2), variceal bleeding (Stage 3), hepatic encephalopathy (Stage 4a), ascites (Stage 4b), and ≥2 different decompensating complications (Stage 5). Multivariate Fine-Gray competing risk survival analysis adjusted for clinicodemographic covariates.

Results

Among 12,196 patients with cirrhosis, the mean (±SD) age was 56.8 (±11.7) years with a follow-up time of 2.35 (±1.81) years. A novel 5-stage disease progression framework was used. The 1-year mortality rates for each stage were 7.3% for Stage 1, 5.4% for Stage 2, 11.4% for Stage 3, 10.0% for Stage 4a, 20.2% for Stage 4b, and 43.8% for Stage 5. Compared to those in Stage 1, Stage 3 (sHR:1.83, 95% CI:1.36–2.48, P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisHumansMiddle AgedMaleFemaleDisease ProgressionUnited StatesRetrospective StudiesAgedAdultRisk FactorsLongitudinal StudiesAscitesHypertension, PortalHepatic EncephalopathyLiver Transplantation

Autor:innen und Institutionen

  • Northwestern University Transplant Outcomes Research Collaborative (NUTORC), Comprehensive Transplant Center (CTC), Northwestern University, Chicago, IL, United States of America.
  • Department of Industrial Engineering and Management Sciences, McCormick School of Engineering, Northwestern University, Evanston, IL, United States of America.
  • Division of Gastroenterology and Hepatology, Department of Medicine, Northwestern University, Chicago, IL, United States of America.
  • Department of Surgery, Center for Health Services and Outcomes Research, Institute of Public Health and Medicine & Northwestern Quality Improvement, Research, & Education in Surgery (NQUIRES), Northwestern University Fe…
  • Center of Innovation for Complex Chronic Healthcare (CINCCH), Edward Hines, Jr. VA Hospital, Hines, IL, United States of America.
  • Division of Biostatistics, Department of Preventative Medicine, Northwestern University, Chicago, IL, United States of America.

ORCID-Profile: Daniela P Ladner

Förderung

  • NHLBI NIH HHS
  • NIA NIH HHS
  • NIDDK NIH HHS
  • National Institute on Aging
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Mohammadi, M., Hasjim, B. J., Balbale, S. N., Polineni, P., Huang, A. A., Paukner, M., Banea, T., Dentici, O., Vitello, D. J., Obayemi, J. E., Duarte-Rojo, A., Nadig, S. N., VanWagner, L. B., Zhao, L., Mehrotra, S., & Ladner, D. P. (2025). Disease trajectory and competing risks of patients with cirrhosis in the US. PLOS ONE. https://doi.org/10.1371/journal.pone.0313152

Vancouver

Mohammadi M, Hasjim BJ, Balbale SN, Polineni P, Huang AA, Paukner M, et al. Disease trajectory and competing risks of patients with cirrhosis in the US. PLOS ONE. 2025. doi:10.1371/journal.pone.0313152

BibTeX
@article{Mohammadi2025,
  author = {Mohammadi, Mohsen and Hasjim, Bima J and Balbale, Salva N and Polineni, Praneet and Huang, Alexander A and Paukner, Mitchell and Banea, Therese and Dentici, Oriana and Vitello, Dominic J and Obayemi, Joy E and Duarte-Rojo, Andrés and Nadig, Satish N and VanWagner, Lisa B and Zhao, Lihui and Mehrotra, Sanjay and Ladner, Daniela P},
  title = {Disease trajectory and competing risks of patients with cirrhosis in the US},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0313152}
}
Kostenlos starten →